Bioengineered Skin Substitutes Market Report 2026

The bioengineered skin substitutes market size has grown rapidly in recent years. It will grow from $2.48 billion in 2025 to $2.82 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to increasing incidence of burn injuries, rising prevalence of chronic wounds, expansion of reconstructive surgical procedures, advancements in tissue engineering techniques, availability of skin substitute products.

The bioengineered skin substitutes market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to increasing demand for regenerative medicine solutions, rising adoption of personalized wound care therapies, expansion of aging population with chronic wounds, growing investments in tissue engineering research, increasing clinical acceptance of bioengineered skin substitutes. Major trends in the forecast period include increasing adoption of bioactive skin regeneration products, rising use of advanced wound healing materials, growing demand for chronic wound treatment solutions, expansion of personalized skin grafting techniques, enhanced focus on biocompatibility and healing outcomes.

The rising number of burn cases is expected to drive the growth of the bioengineered skin substitutes market in the coming years. Burn injuries occur when the skin or other tissues are damaged due to heat, radiation, electricity, friction, or chemicals. Causes include insufficient safety measures, improper handling of flammable materials, and limited awareness of fire hazards and safety protocols. Bioengineered skin substitutes offer temporary or permanent coverage for damaged skin, promoting healing, reducing infection risk, and improving functional and cosmetic outcomes. For example, in October 2023, according to the International Burn Injury Database (iBID), a UK-based national registry covering NHS specialized burn services in England and Wales, burn and scald injuries to children in the first half of 2023 increased by 45% compared with the same period in 2022, while burns and scalds among adults and the elderly from hot water bottles rose by 19%. Therefore, the increasing incidence of burn cases is fueling the bioengineered skin substitutes market.

Leading companies in the bioengineered skin substitutes market are developing innovative products, such as fish skin grafts, to improve the effectiveness and versatility of skin substitutes. Fish-skin grafts are wound-healing materials derived from processed fish skin that support tissue regeneration and repair. For instance, in February 2024, Kerecis, an Iceland-based wound care company, launched Shield Standard, a bioengineered skin substitute combining intact fish skin with a silicone backing. The product serves as a natural scaffold for healing, with minimal processing to retain the beneficial components of fish skin that promote tissue regeneration. It offers biocompatibility with human skin, natural moisture retention, and reduced infection risk, making it suitable for treating various wounds, including acute and chronic injuries.

In August 2023, Coloplast A/S, a Denmark-based healthcare company, acquired Kerecis for $1.3 billion. This acquisition strengthens Coloplast’s position in the advanced wound care market, particularly within the high-growth US-focused biologics segment. Kerecis is an Iceland-based manufacturer specializing in fish-derived bioengineered skin substitutes and other skin-based therapeutic products.

Major companies operating in the bioengineered skin substitutes market are Smith & Nephew Plc, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation, Gunze Limited, Organogenesis Inc., LifeNet Health Inc., MiMedx Group Inc., Vericel Corporation, AlloSource Inc., Sientra Inc., PolyNovo Limited, Avita Medical Limited, Tissue Regenix Group, Amarantus Bioscience Holdings Inc., PolarityTE, Promethean LifeSciences Inc., Medline Industries, Mölnlycke Health Care, DermTech Inc., Acelity Inc., Kerecis, Stratatech Corporation.

North America was the largest region in the bioengineered skin substitutes market in 2025. The regions covered in the bioengineered skin substitutes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioengineered skin substitutes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bioengineered skin substitutes market by increasing costs of imported biomaterials, cell culture media, biopolymers, laboratory equipment, and sterile packaging components. Healthcare providers and manufacturers in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces higher production costs for advanced skin substitute products. These tariffs are increasing treatment costs and slowing product commercialization timelines. However, they are also encouraging local biomaterial production, regional manufacturing capabilities, and increased investment in domestic regenerative medicine infrastructure.

The bioengineered skin substitutes market research report is one of a series of new reports that provides bioengineered skin substitutes market statistics, including bioengineered skin substitutes industry global market size, regional shares, competitors with a bioengineered skin substitutes market share, detailed bioengineered skin substitutes market segments, market trends and opportunities, and any further data you may need to thrive in the bioengineered skin substitutes industry. This bioengineered skin substitutes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioengineered skin substitutes are artificially created or laboratory-grown skin materials made from biological, synthetic, or hybrid components designed to mimic the structure and function of human skin. They are primarily used to treat severe skin injuries or conditions that require skin replacement or regeneration, including burns, chronic wounds, ulcers, and reconstructive surgeries.

The main types of bioengineered skin substitutes include acellular, allogeneic, xenogeneic, autologous, and others. Acellular skin substitutes are derived from skin tissues with all cellular material removed, leaving only the extracellular structure. These products are applied to acute and chronic wounds and are utilized by a variety of end users, such as wound care centers, hospitals, specialty clinics, and other healthcare facilities.

The bioengineered skin substitutes market consists of sales of products including apligraf, dermagraft, epicel, transcyte, and orcel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.